未经证实:某些甲状腺癌患者的临床结果并不总是有利的。探讨叉头盒家族对甲状腺癌免疫细胞浸润和肿瘤微环境的影响。因此研究了FOXP2在肿瘤侵袭和复发中的作用。
未经证实:TIMER和GEPIA首次用于比较FOXPs在多种人类癌症的正常和癌组织中的表达。通过实时定量PCR和Westernblot在匹配的甲状腺癌和癌旁正常组织中证实了数据库的结果,除了一组甲状腺癌细胞系和正常甲状腺细胞。采用GEPIA平台发现FOXPs作为预后指标的可能性。然后使用TISIBD和UACLCAN来评估FOXPs对淋巴结转移和肿瘤分期的影响。GEPIA分析最初用于分析FOXPs与肿瘤免疫浸润细胞的相关性,然后纳入TIMER数据集,根据肿瘤纯度进行标准化。
UNASSIGNED:FOXPs的不同成员在各种癌组织中表达差异。与匹配的正常组织相比,甲状腺癌组织中的FOXP1,FOXP2水平较低,FOXP3,FOXP4水平较高。FOXP2、FOXP4与免疫侵袭呈负相关,FOXP1和FOXP3呈正相关。FOXPs与多种免疫细胞表现出显著的相关性。更重要的是,只有FOXP2对复发和肿瘤分期有显著影响。
未经批准:作为免疫调节因子,FOXP2的减少可能影响肿瘤微环境和免疫细胞浸润,增强肿瘤免疫逃逸,并促进甲状腺癌的复发。FOXP2可能是一种新的潜在诊断和预后标志物。
UNASSIGNED: The clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and tumor microenvironment in thyroid cancer was explored. The role of
FOXP2 in tumor invasion and recurrence was investigated consequently.
UNASSIGNED: TIMER and GEPIA were firstly employed to compare FOXPs expression in normal and cancer tissues from multiple human cancers. The results from database were confirmed by quantitative Real Time-PCR and Western blot in matched thyroid cancer and adjacent normal tissues, in addition to a panel of thyroid cancer cell lines and normal thyroid cell. GEPIA platform was employed to discover the possibility of FOXPs as prognostic indicator. TISIBD and UACLCAN were then employed to estimate the influence of FOXPs on lymph node metastasis and tumor staging. GEPIA analysis was initially employed to analyze correlation of FOXPs and tumor immune infiltrating cells, and TIMER dataset was then included for standardization according to tumor purity.
UNASSIGNED: Different member of FOXPs showed divergence in expression in various cancer tissues. Lower FOXP1,
FOXP2 and higher FOXP3, FOXP4 levels could be identified in thyroid cancer tissues when compared with matched normal tissue. There was an inverse correlation between
FOXP2, FOXP4 and immune invasion, whereas FOXP1 and FOXP3 were positively correlated. FOXPs showed remarkable correlations with multiply immune cells. More importantly, only
FOXP2 showed the significant effect on recurrence and tumor staging.
UNASSIGNED: As immune regulatory factor, the reduction of FOXP2 may affect tumor microenvironments and immune cells infiltration, enhance tumor immune escape, and promote recurrence of thyroid cancer.
FOXP2 could be a new potential diagnostic and prognostic marker.